TY - JOUR
T1 - Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
AU - Gentile, Massimo
AU - Shanafelt, Tait D
AU - Mauro, Francesca Romana
AU - Reda, Gianluigi
AU - Rossi, Davide
AU - Laurenti, Luca
AU - Del Principe, Maria Ilaria
AU - Cutrona, Giovanna
AU - Angeletti, Ilaria
AU - Coscia, Marta
AU - Herishanu, Yair
AU - Chiarenza, Annalisa
AU - Molica, Stefano
AU - Ciolli, Stefania
AU - Goldschmidt, Neta
AU - Angrilli, Francesco
AU - Giordano, Annamaria
AU - Rago, Angela
AU - Bairey, Osnat
AU - Tripepi, Giovanni
AU - Chaffee, Kari G
AU - Sameer, Parikh A
AU - Vigna, Ernesto
AU - Zirlik, Katja
AU - Shvidel, Lev
AU - Innocenti, Idanna
AU - Recchia, Anna Grazia
AU - Di Raimondo, Francesco
AU - Del Poeta, Giovanni
AU - Cortelezzi, Agostino
AU - Neri, Antonino
AU - Ferrarini, Manlio
AU - Gaidano, Gianluca
AU - Kay, Neil E
AU - Polliack, Aaron
AU - Foà, Robin
AU - Morabito, Fortunato
PY - 2018
Y1 - 2018
N2 - An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
AB - An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
KW - CLL-IPI
KW - PFS
KW - chemo-immunotherapy
KW - chronic lymphocytic leukemia
KW - prognosis
KW - progression-free survival
KW - CLL-IPI
KW - PFS
KW - chemo-immunotherapy
KW - chronic lymphocytic leukemia
KW - prognosis
KW - progression-free survival
UR - https://publicatt.unicatt.it/handle/10807/135006
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85052966783&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052966783&origin=inward
U2 - 10.1111/ejh.13149
DO - 10.1111/ejh.13149
M3 - Article
SN - 1600-0609
SP - N/A-N/A
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 24
ER -